LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 180

Search options

  1. Book ; Online ; E-Book: Oncology

    Oh, William K. / Chari, Ajai

    potential pitfalls/common mistakes, clinical pearls, management algorithms, evidence-based guidelines

    (Mount Sinai expert guides)

    2019  

    Author's details edited by William K. Oh, Ajai Chari
    Series title Mount Sinai expert guides
    Keywords Oncology / Handbooks, manuals, etc ; Medical Oncology / methods ; Neoplasms
    Language English
    Size 1 Online-Ressource (xxviii, 597 Seiten), Illustrationen
    Publisher Wiley Blackwell
    Publishing place Hoboken, NJ
    Publishing country United States
    Document type Book ; Online ; E-Book
    Note Includes bibliographical references and index
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT020329395
    ISBN 978-1-119-18959-6 ; 978-1-119-18958-9 ; 978-1-119-18957-2 ; 9781119189558 ; 1-119-18959-4 ; 1-119-18958-6 ; 1-119-18957-8 ; 1119189551
    DOI 10.1002/9781119189596
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Full text online

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Role of Consolidation and Maintenance.

    Kumar, Anupama D / Chari, Ajai

    Hematology/oncology clinics of North America

    2024  Volume 38, Issue 2, Page(s) 421–440

    Abstract: Consolidation therapy consists of short-term therapy after stem cell transplant in multiple myeloma. Key consolidation trials have shown mixed results on whether consolidation should be included after transplant, leading to varied clinical practice. ... ...

    Abstract Consolidation therapy consists of short-term therapy after stem cell transplant in multiple myeloma. Key consolidation trials have shown mixed results on whether consolidation should be included after transplant, leading to varied clinical practice. Maintenance therapy consists of long-term, typically fixed-duration or indefinite, therapy. Standard-risk patients typically receive single-agent therapy, whereas high-risk may benefit from doublet therapy and beyond. Adverse events and quality of life concerns should be considered, as optimal duration of maintenance therapy continues to be studied.
    MeSH term(s) Humans ; Quality of Life ; Multiple Myeloma/therapy ; Stem Cell Transplantation ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Transplantation, Autologous ; Maintenance Chemotherapy/adverse effects ; Maintenance Chemotherapy/methods ; Hematopoietic Stem Cell Transplantation/methods ; Consolidation Chemotherapy/methods
    Language English
    Publishing date 2024-01-22
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 93115-9
    ISSN 1558-1977 ; 0889-8588
    ISSN (online) 1558-1977
    ISSN 0889-8588
    DOI 10.1016/j.hoc.2023.12.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 1077: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma.

    Lonial, Sagar / Bowser, Andrew D / Chari, Ajai / Costello, Caitlin / Krishnan, Amrita / Usmani, Saad Z

    Clinical lymphoma, myeloma & leukemia

    2023  Volume 23, Issue 11, Page(s) 815–824

    Abstract: Introduction: Multiple myeloma is a hematologic malignancy that is typically associated with recurrent relapses. There are numerous frontline treatment regimens that are highly effective for individual patients. The introduction of anti-CD38 monoclonal ... ...

    Abstract Introduction: Multiple myeloma is a hematologic malignancy that is typically associated with recurrent relapses. There are numerous frontline treatment regimens that are highly effective for individual patients. The introduction of anti-CD38 monoclonal antibody therapy has shifted treatment decision-making in this setting, with many centers now considering the use of daratumumab as part of initial therapy regardless of patient eligibility for autologous stem cell transplantation (ASCT). Daratumumab has demonstrated clinical efficacy and acceptable toxicity in the first and later lines of therapy, increasing complexity in treatment selection and sequencing. Although daratumumab-containing regimens may not be appropriate for every patient, it is increasingly recognized that the most effective regimens should be used upfront, as high rates of attrition mean that many patients in real-world practice may see a limited number of lines of therapy.
    Methods: A panel of experts in multiple myeloma was convened to consider current evidence and treatment practices to inform a series of consensus statements on the optimal management of newly diagnosed multiple myeloma, including not only treatment selection, but the need for infection prophylaxis, route of administration, and mitigation of potential infusion-related reactions, among other clinical challenges.
    Results/conclusions: The goal of the present review article is to encapsulate these consensus statements and the rationale for their development, which altogether may help inform treatment selection and clinical decision-making in the front line.
    MeSH term(s) Humans ; Multiple Myeloma/diagnosis ; Multiple Myeloma/drug therapy ; Hematopoietic Stem Cell Transplantation ; ADP-ribosyl Cyclase 1 ; Transplantation, Autologous ; Neoplasm Recurrence, Local/drug therapy ; Antineoplastic Agents/therapeutic use ; Antibodies, Monoclonal ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
    Chemical Substances daratumumab (4Z63YK6E0E) ; ADP-ribosyl Cyclase 1 (EC 3.2.2.6) ; Antineoplastic Agents ; Antibodies, Monoclonal
    Language English
    Publishing date 2023-07-10
    Publishing country United States
    Document type Review ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2023.07.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Imipridone ONC201: combination therapy in hematologic malignancies.

    Chari, Ajai / Barlogie, Bart

    Cell cycle (Georgetown, Tex.)

    2018  Volume 17, Issue 16, Page(s) 1947–1948

    MeSH term(s) Hematologic Neoplasms ; Heterocyclic Compounds, 4 or More Rings ; Humans ; Neoplasms
    Chemical Substances Heterocyclic Compounds, 4 or More Rings ; TIC10 compound (9U35A31JAI)
    Language English
    Publishing date 2018-09-11
    Publishing country United States
    Document type News ; Comment
    ZDB-ID 2146183-1
    ISSN 1551-4005 ; 1538-4101 ; 1554-8627
    ISSN (online) 1551-4005
    ISSN 1538-4101 ; 1554-8627
    DOI 10.1080/15384101.2018.1490861
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5881: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.

    Rodriguez-Otero, Paula / van de Donk, Niels W C J / Pillarisetti, Kodandaram / Cornax, Ingrid / Vishwamitra, Deeksha / Gray, Kathleen / Hilder, Brandi / Tolbert, Jaszianne / Renaud, Thomas / Masterson, Tara / Heuck, Christoph / Kane, Colleen / Verona, Raluca / Moreau, Philippe / Bahlis, Nizar / Chari, Ajai

    Blood cancer journal

    2024  Volume 14, Issue 1, Page(s) 40

    Language English
    Publishing date 2024-03-06
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-024-01018-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Selinexor for Refractory Multiple Myeloma. Reply.

    Chari, Ajai / Vogl, Dan T / Jagannath, Sundar

    The New England journal of medicine

    2019  Volume 381, Issue 20, Page(s) 1977–1978

    MeSH term(s) Dexamethasone ; Humans ; Hydrazines ; Multiple Myeloma ; Triazoles
    Chemical Substances Hydrazines ; Triazoles ; selinexor (31TZ62FO8F) ; Dexamethasone (7S5I7G3JQL)
    Language English
    Publishing date 2019-10-29
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc1912625
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.

    Derman, Benjamin A / Chari, Ajai / Zonder, Jeffrey / Major, Ajay / Stefka, Andrew T / Jiang, Ken / Karrison, Theodore / Jasielec, Jagoda / Jakubowiak, Andrzej

    European journal of haematology

    2023  Volume 110, Issue 5, Page(s) 564–570

    Abstract: We performed a phase I study of weekly selinexor, carfilzomib, and dexamethasone (wSKd) in patients with relapsed/refractory multiple myeloma (MM). The primary objective was to identify the maximum tolerated dose (MTD) of wSKd. Secondary endpoints ... ...

    Abstract We performed a phase I study of weekly selinexor, carfilzomib, and dexamethasone (wSKd) in patients with relapsed/refractory multiple myeloma (MM). The primary objective was to identify the maximum tolerated dose (MTD) of wSKd. Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Prior exposure/refractoriness to carfilzomib was permitted. Thirty patients were enrolled; 26 (87%) had triple-class exposed disease and 6 (20%) received chimeric antigen receptor (CAR) T-cell therapy. Dose level 2 (carfilzomib 70 mg/m
    MeSH term(s) Humans ; Multiple Myeloma/diagnosis ; Multiple Myeloma/drug therapy ; Dexamethasone ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
    Chemical Substances carfilzomib (72X6E3J5AR) ; selinexor (31TZ62FO8F) ; Dexamethasone (7S5I7G3JQL)
    Language English
    Publishing date 2023-02-15
    Publishing country England
    Document type Clinical Trial, Phase I ; Journal Article
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/ejh.13937
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 323: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Selinexor in relapsed/refractory multiple myeloma.

    Richter, Joshua / Madduri, Deepu / Richard, Shambavi / Chari, Ajai

    Therapeutic advances in hematology

    2020  Volume 11, Page(s) 2040620720930629

    Abstract: Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and ... ...

    Abstract Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies, patients ultimately relapse. Selinexor is a first-in-class exportin-1 inhibitor with activity in these multiply relapsed and refractory patients. Although the current Food and Drug Administration (FDA) approval is for the doublet of Selinexor in combination with dexamethasone, ongoing clinical trials are evaluating a number of combination regimens. These triplet and quadruplet, selinexor-based, regimens are showing significant activity in "triple-class" refractory patients. With appropriate combination drug choice, drug dosing, and supportive measures, patients with previously no viable options for therapy, now have multiple potential regimens to control their disease.
    Language English
    Publishing date 2020-06-09
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2585183-4
    ISSN 2040-6215 ; 2040-6207
    ISSN (online) 2040-6215
    ISSN 2040-6207
    DOI 10.1177/2040620720930629
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.

    Theodoropoulos, Nicholas / Lancman, Guido / Chari, Ajai

    Targeted oncology

    2020  Volume 15, Issue 6, Page(s) 697–708

    Abstract: Multiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course characterized by multiple relapses and treatment refractoriness. While recent treatment advancements have extended overall survival (OS), refractory MM has a poor ... ...

    Abstract Multiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course characterized by multiple relapses and treatment refractoriness. While recent treatment advancements have extended overall survival (OS), refractory MM has a poor prognosis, with a median OS of between 4 and 6 months. Nuclear export inhibition, specifically inhibition of CRM1/XPO1, is an emerging novel treatment modality that has shown promise in treatment-refractory MM. Initially discovered in yeast in 1983, early clinical applications were met with significant toxicities that limited their utility. The creation of small molecule inhibitors of nuclear export (SINE) has improved on toxicity limitations and has led to investigation in a number of malignancies at the preclinical and clinical stages. Preclinical studies of SINEs in MM have shown that these molecules are cytotoxic to myeloma cells, play a role in therapy resensitization, and suggest a role in limiting bone disease progression. In July 2019, selinexor became the first nuclear export inhibitor approved for use in relapsed/refractory MM based on the STORM trial. As of May 2020, there were eight ongoing trials combining selinexor with standard treatment regimens in relapsed/refractory MM. Eltanexor, a second-generation SINE, is also under investigation and has shown preliminary signs of efficacy in an early clinical trial while potentially having an improved toxicity profile compared with selinexor. Results in ongoing trials will help further define the role of SINEs in MM.
    MeSH term(s) Active Transport, Cell Nucleus/drug effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Multiple Myeloma/drug therapy ; Multiple Myeloma/genetics
    Keywords covid19
    Language English
    Publishing date 2020-10-16
    Publishing country France
    Document type Journal Article ; Review
    ZDB-ID 2222136-0
    ISSN 1776-260X ; 1776-2596
    ISSN (online) 1776-260X
    ISSN 1776-2596
    DOI 10.1007/s11523-020-00758-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Bispecifics, trispecifics, and other novel immune treatments in myeloma.

    Lancman, Guido / Richter, Joshua / Chari, Ajai

    Hematology. American Society of Hematology. Education Program

    2020  Volume 2020, Issue 1, Page(s) 264–271

    Abstract: Despite recent advances in treatment, relapses in multiple myeloma (MM) are inevitable. Off-the-shelf immunotherapeutics represent a promising avenue for research, with various classes of agents under development and several demonstrating deep and ... ...

    Abstract Despite recent advances in treatment, relapses in multiple myeloma (MM) are inevitable. Off-the-shelf immunotherapeutics represent a promising avenue for research, with various classes of agents under development and several demonstrating deep and durable responses in patients who have exhausted all available therapies. Antibody-drug conjugates (ADCs) seek to improve on naked monoclonal antibodies by delivering a cytotoxic payload directly to tumor cells while largely limiting systemic effects. Belantamab mafodotin, a B-cell maturation antigen (BCMA)-targeted ADC, has shown response rates >30% in a phase 2 trial of highly refractory patients and is being investigated in a variety of settings and combinations. Several other ADCs are in earlier stages of development that target cell surface antigens that are internalized, including BCMA, CD38, CD46, CD56, CD74, and CD138. Bispecifics are designed to bring cytotoxic immune effector cells into proximity with tumor cells, and several agents have shown high response rates in early trials. Current targets include BCMA, CD38, GPRC5d, and FCRH5, and all of these seek to engage T cells through CD3. Bispecifics targeting natural killer (NK) cells through CD16 are still in preclinical development. Trispecific antibodies may represent an advance over bispecifics by providing a T-cell costimulatory signal such as CD28, or alternatively, dual MM antigens to increase specificity of NK or T-cell targeting. This is an area of active preclinical research at this time. Lastly, designed ankyrin repeat proteins, which are small antibody-mimetic proteins with high target-binding affinity, have the potential to block multiple pathways at once and provide stimulatory signals to the immune system.
    MeSH term(s) Aged ; Antibodies, Bispecific/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antigens, Neoplasm/immunology ; Female ; Humans ; Immunoconjugates/therapeutic use ; Immunotherapy ; Multiple Myeloma/therapy ; Neoplasm Recurrence, Local
    Chemical Substances Antibodies, Bispecific ; Antibodies, Monoclonal, Humanized ; Antigens, Neoplasm ; Immunoconjugates ; belantamab mafodotin (DB1041CXDG)
    Language English
    Publishing date 2020-12-03
    Publishing country United States
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 2084287-9
    ISSN 1520-4383 ; 1520-4391
    ISSN (online) 1520-4383
    ISSN 1520-4391
    DOI 10.1182/hematology.2020000110
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top